IceCure Medical Announces 1-for-30 Reverse Stock Split to Regain Nasdaq Compliance

summarizeSummary

IceCure Medical announced a 1-for-30 reverse stock split, effective June 4, 2026, to meet Nasdaq's minimum bid price requirement and avoid delisting.

check_boxKey Events

• 1-for-30 Reverse Stock Split Approved

  The company will effect a 1-for-30 reverse share split, reducing outstanding shares from 84.2 million to approximately 2.8 million. This action follows shareholder approval at a Special General Meeting on May 11, 2026.

• Nasdaq Compliance Requirement

  The primary purpose of the reverse split is to increase the per-share trading price to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The company has until November 9, 2026, to cure the non-compliance.

• Effective Trading Date

  Trading on a split-adjusted basis will commence when the market opens on June 4, 2026.

• Context of Financial Distress

  This aggressive reverse split comes as the company's stock trades near its 52-week low and follows a prior disclosure of substantial doubt about its ability to continue as a going concern.

auto_awesomeAnalysis

This reverse stock split is a critical measure for IceCure Medical to regain compliance with Nasdaq's minimum bid price requirement, following shareholder approval on May 11, 2026. The aggressive 1-for-30 ratio highlights the significant decline in share price and the urgency to maintain its listing, especially given the company's prior disclosure of substantial doubt about its ability to continue as a going concern. Maintaining Nasdaq listing is crucial for future capital raising efforts, particularly with the existing $100 million shelf registration.